How Syngene synthesized a complex cyclic peptide for use in novel drug therapies
Overview Syngene partnered with a US client to synthesize a complex 11-mer cyclic peptide. The client’s peptide had several N-methylated amino acids, α,α-disubstituted amino acids, and unnatural amino acids, which posed several challenges in peptide synthesis. Syngene peptide chemists decided to relook at the best possible starting point for making the cyclic peptide. The team […]
How Syngene screened inhibitors of protein-protein interaction in HTS mode for accelerated drug discovery
The Challenge A biotech company approached Syngene to develop an HTRF assay for screening inhibitors of protein-protein interaction in high throughput screening (HTS) mode. We were required to screen 50,000 compounds against two different transcription factors in a challenging megadalton-size multiprotein complex. Another requirement was to establish a counter-screen for identifying interfering compounds. Syngene was […]
Harnessing Targeted Protein Degradation driving programs to candidate delivery stage for a leading biotech
Business Problem One of the leading biotech companies working in the targeted protein degradation space was looking for partners to help them scale quickly. The key criteria they set out were fast delivery of the compounds, ability to quickly solve chemistry problems, open, transparent and on-time communication and flexibility and ability to scale. The key […]
A quick, cost-effective process for large-scale compound synthesis for a leading pharma company
Summary Pharmaceutical companies are under immense pressure to develop drugs for unmet medical needs while improving processes to shortentimelines and minimize costs. This case study explains how Syngene minimized costs while ensuring quick turn-around time when scaling a client’s compound from lab-scaleto cGMP- scale. Syngene not only delivered as per timelines but also increased yield […]
How Syngene helped develop the world’s first drug for a rare disease affecting children
Overview Syngene, a leading global CRO/CDMO, partnered with a U.S.-based rare disease company to develop and manufacture a first-in-class treatment for a rare disease affecting children. Syngene successfully developed the manufacturing process for the drug and supplied the required quantities to assist the company during different phases of drug development (preclinical and clinical) and later […]
How collaboration with Syngene helped a global biopharma fast-track novel molecule development for global licensing
Summary A global biopharma company partnered with Syngene for Bioanalytical studies for PK, ADA and NAb assays. In less than a year of the collaboration, the company decided to make Syngene, its preferred CRO lab for a novel molecule for migraine. The molecule went on to receive FDA approval in 2018. Bolstered by the success […]
How Syngene developed a multi-drug combination, antiparasitic drug for dogs for a leading Animal Health company
Overview Syngene had developed a formula for a leading Animal Healthcare company using a multi antiparasitic drug combination to treat dogs suffering from ticks, roundworm,hookworm, pinworm, and other worm infections. The client asked Syngene to develop and manufacture clinical supplies of the formulation. Syngene successfully manufactured clinical supplies of the flavored tablets with multiple APIs […]
How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months
Overview A biotech company had generated a strong pipeline of candidates for gut-brain diseases and was looking for the right preclinical partner for short and long-term SafetyAssessment studies. Syngene’s Safety Assessment team supported the client’s drug development program through multiple exploratory toxicity studies, four IND-enabling safety tox studies, and three 90-day toxicity studies in rodent […]
How Syngene accelerated drug discovery against a protein target using HTS
The Challenge A biotech company had developed a fluorescence polarization assay. The company approached Syngene to transfer the assay in an HTS-ready manner and screen a library of 200,000 compounds against a single protein target. Syngene was required to deliver the relevant compounds against a very tight deadline while ensuring high-quality output. The Solution Syngene […]
How Syngene helped Panbela achieve shorter production time for its pancreatic cancer drug
Overview Panbela Therapeutics Inc. (“Panbela”) is a biopharma company focused on developing small molecule therapeutics for oncology indications. Before partnering with Syngene, Panbela was producing its small molecule candidate SBP-101 for pancreatic cancer using a 15-synthetic step literature preparation. When Panbela approached Syngene for the chemical development of its molecule, we recommended a chiral purity […]